Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia

JC Wang, HD Lang, S Lichter… - British journal of …, 1992 - Wiley Online Library
JC Wang, HD Lang, S Lichter, M Weinstein, P Benn
British journal of haematology, 1992Wiley Online Library
Cytogenetic studies of bone marrow fibroblasts and blood cells from peripheral blood or
bone marrow were performed in 19 patients with myelofibrosis with myeloid metaplasia
(group 1), nine patients with other myeloproliferative syndromes without myelofibrosis
(group 2), and 12 patients with anaemia secondary to iron deficiency or chronic
inflammatory disease (group 3). Clonal cell populations with abnormal karyotypes were
seen in the bone marrow or blood in five of 14 (36%) group 1 patients, one of nine (11%) …
Summary
Cytogenetic studies of bone marrow fibroblasts and blood cells from peripheral blood or bone marrow were performed in 19 patients with myelofibrosis with myeloid metaplasia (group 1), nine patients with other myeloproliferative syndromes without myelofibrosis (group 2), and 12 patients with anaemia secondary to iron deficiency or chronic inflammatory disease (group 3). Clonal cell populations with abnormal karyotypes were seen in the bone marrow or blood in five of 14 (36%) group 1 patients, one of nine (11%) group 2 patients and none (0%) of the group 3 patients. Abnormal karyotypes of bone marrow fibroblasts were found in three of 16 (19%) of patients of group 1, and in two of nine (22%) and two of 12 (17%) patients each of groups 2 and 3, respectively. Since abnormal karyotypes can be found in bone marrow fibroblasts cultured from normal subjects, and since the abnormalities seen in the bone marrow fibroblasts differed from those found in bone marrow or blood cells, it is suggested that abnormal karyotypes found in bone marrow fibroblasts cultured from patients with primary myelofibrosis do not necessarily reflect neoplasia. The results of this study are compatible with the widely accepted hypothesis that in patients presenting with ‘primary’ myelofibrosis, the fibrosis is a secondary reactive process.
Wiley Online Library